## **Experiment Number:** S0553

Species/Strain: Mouse/B6C3F1

Route: Gavage

# **Toxicokinetics Data Summary**

Test Compound: 3'-Azido-3'-deoxythymidine/Rifampicin

**CAS Number:** AZTRIFAMPIN

Date Report Requested: 11/09/2016 Time Report Requested: 14:05:43

Lab: Research Triangle Institute

### Male

	Treatment Groups (mg/kg)			
	100#	100~	100 *	
	Plasma			
C <sub>max(obs)</sub> (ug/mL)		0.500	1.14	
T <sub>max(obs)</sub> (minute)		10	20	
t <sub>1/2(Beta)</sub> (minute)	27.0			
Cl <sub>1(F)</sub> (mL/min/kg)	32.6			
MRT (minute)	38.1			
AUC <sub>0-t</sub> (ug*min/mL)		47.3	49.8	
AUC <sub>inf</sub> (ug*min/mL)	3069			
F (fraction)	0.86			

## Experiment Number: S0553

Route: Gavage

Species/Strain: Mouse/B6C3F1

## **Toxicokinetics Data Summary**

Test Compound: 3'-Azido-3'-deoxythymidine/Rifampicin

**CAS Number:** AZTRIFAMPIN

Date Report Requested: 11/09/2016 Time Report Requested: 14:05:43

Lab: Research Triangle Institute

	Treatment Groups (mg/kg)					
	100#	100~	100 *			
		Plasma				
C <sub>max(obs)</sub> (ug/mL)		0.347	0.582			
T <sub>max(obs)</sub> (minute)		20	20			
t <sub>1/2(Beta)</sub> (minute)	25.0					
Cl <sub>1(F)</sub> (mL/min/kg)	35.5					
MRT (minute)	39.3					
AUC <sub>0-t</sub> (ug*min/mL)		56.4	21.3			
AUC <sub>inf</sub> (ug*min/mL)	2816					
F (fraction)	0.66					

### **Toxicokinetics Data Summary**

**Test Compound:** 3'-Azido-3'-deoxythymidine/Rifampicin

Species/Strain: Mouse/B6C3F1 CAS Number: AZTRIFAMPIN

Date Report Requested: 11/09/2016 Time Report Requested: 14:05:43 Lab: Research Triangle Institute

#### **LEGEND**

Route: Gavage

**Experiment Number: S0553** 

Data are displayed as mean ± SEM

MODELING METHOD & BEST FIT MODEL

PCNONLIN software Version 4.2, SCI Software, Apex, NC; non-compartmental analysis

#### **ANALYTE**

- # 3'-Azido-3'-deoxythymidine
- \* 3'-Azido-3'-deoxy-5'-beta-D-glucopyranurosylthymidine
- ~ 3'-Amino-3'-deoxythimidine

#### TK PARAMETERS

C<sub>max(obs)</sub> = Observed or Predicted Maximum plasma (or tissue) concentration

 $T_{max(obs)}$  = Time at which  $C_{max}$  predicted or observed occurs

 $t_{\frac{1}{2}(\text{beta})}$  = Half-life for the beta phase

 $\text{Cl}_{1(F)}$  = Apparent clearance of the central compartment, also  $\text{Cl}_{(F)}$  for gavage groups in non-compartmental

model

MRT = Mean residence time

 $AUC_{0-t}$  = Area under the plasma concentration versus time curve, AUC, from time  $t_i$  (initial) to  $t_f$  (final),  $AUC_{last}$ 

AUCinf = Area under the plasma concentration versus time curve, AUC, extrapolated to time equals infinity

F = Bioavailability, absolute bioavailability

\*\* END OF REPORT \*\*